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Abstract
Оur task in the field of new derivatives of amidoximes was the elaboration for
new medication with increased activity and lower toxicity than medications used in
practice. Here are the results of the search for new painkillers and antitubercular
and antidiabetic drugs in the class of amidoxime derivatives. Nitrous derivatives of
α-chloro-α-isonitrosoacetone, O-aroyl-β-aminopropioamidoximes, and 3-[β-(piper-
idine-1-yl)]ethyl-5-aryl-1,2,4-oxadiazoles were tested for conduction, infiltration,
and terminal anesthesia. Among them hit compounds were discovered. The search
for new anti-TB drugs is executed in the world. Salts and bases of O-aroylation
products of β-(thiomorpholin-1-yl) and β-(4-methylpiperazin-1-yl)
propioamidoximes during in vitro antitubercular screening for DS, DR, and MDR
strains ofM. tuberculosis manifest themselves as highly active competitive com-
pounds. In the series of the derivatives of β-aminopropioamidoximes, a search for
new antidiabetic drugs was done. The compounds with pronounced antidiabetic
properties were revealed. The obtained data of the most promising samples with a
preliminary assessment of their average toxic dose in animals can be used in further
in vivo testing of infiltration anesthesia conditions, of antidiabetic properties, and at
the development of doses and new treatment regimens for TB.
Keywords: nitrous derivatives of α-chloro-α-isonitrosoacetone, bases and salts of
O-aroyl-β-aminopropioamidoximes, 3-(β-amino)ethyl-5-aryl-1,2,4-oxadiazoles,
local anesthetics, in vitro antitubercular, antidiabetic screening
1. Introduction
First of all, researchers’ interest in amidoximes is due to the possibility of their
synthetic modification according to the reaction groups NOH and NH2. The largest
number of derivatives was obtained as a result of acylation reactions at the O-atom
of the NOH group and subsequent transformations involving the NH2 fragment to
1,2,4-oxadiazoles [1]. In most cases, amidoxime derivatives, including heterocyclic
radicals, under standard conditions are stable, allowing their structural identifica-
tion, and withstand storage and biological screening. Arrays of data were obtained
on their diverse biological activity: antitubercular, local anesthetic, antidiabetic,
antioxidant, etc. [2, 3].
The rational use of drugs is one of the urgent problems of modern medicine.
A doctor of any profile most often faces the need to eliminate and prevent pain.
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With pain of varying intensities, adequate pain relief reduces the patient’s tension
and fear, prevents him from forming a negative attitude to medical manipulations,
and protects the nervous system of the doctor and patient, providing better medical
care. The search for new painkillers with increased activity and lower toxicity than
painkillers used in practice is one of the tasks of modern medical chemistry. We
developed new β-aminopropioamidoximes and studied their neurotropic proper-
ties. Herein we present results from a study of the local anesthetic activities of three
chemical groups of new amidoxime derivatives [4].
Tuberculosis (TB) is the leading cause of death and morbidity in more than one
third of the world’s population. Of the 56.4 million deaths worldwide due to the 10
leading causes in 2016, tuberculosis ranked 10th, from which 1.4 million people
died [5].
In May 2014, the World Health Organization (WHO) approved a new global TB
control strategy “End TB”. This strategy marks a critical shift from tuberculosis
control to ending the epidemic by 2035. The “End TB” strategy emphasizes the need
for innovation to accelerate progress by optimizing existing ones in the short term
and introducing new innovative modes in the long term [6]. In order to reduce the
duration of treatment, the rapid development of drug resistance and toxic and side
effects of existing anti-TB drugs, and to reduce the cost of extremely expensive
treatment of TB (DS, MDR, XDR), the world is searching for new anti-TB drugs.
We have synthesized the salts and bases of the O-aroylation products of
β-(thiomorpholin-1-yl) and β-(4-methylpiperazin-1-yl)propioamidoximes,
containing in the β-position pharmacophore fragments of 1-methylpiperazine and
thiomorpholine. In vitro antitubercular screening of β-aminopropioamidoxime
derivatives in the DS, DR, and MDR strains ofM. tuberculosis revealed highly active
competitive compounds which are less toxic than rifampicin and isoniazid with
activity significantly exceeding the activity of the reference preparations. It is
assumed that these compounds may be the subject of subsequent trials in the
development of doses and new treatment regimens for TB [7, 8].
Diabetes is on the rise across the globe. Presently every 7 seconds someone is
estimated to die from diabetes or its complications. This is against the background
of a global diabetes prevalence of 8.8% of the world population in 2017. The prev-
alence is expected to further increase to 9.9% by the year 2045. In total numbers,
this reflects a population of 424.9 million people with diabetes worldwide in 2017
with an estimate of a 48% increase to 628.6 million people for the year 2045 [9].
Due to the urgency of the problem of diabetes in the world, a search is underway for
new antidiabetic drugs. The antidiabetic activity of amidoxime derivatives is known
[10, 11]. We conducted in vitro testing of derivatives of β-aminopropioamidoximes:
bases and pharmacologically acceptable salts of O-aroyl-β-(morpholin-1-yl)
propioamidoxime and 5-aryl-3-β-(piperidin-1-yl and morpholin-1-yl)ethyl-1,2,4-
oxadiazoles with respect to their ability to inhibit the activity of α-amylase and
α-glucosidase enzymes. Identified compounds with pronounced antidiabetic
properties must be noted; a series of 3,5-disubstituted 1,2,4-oxadiazoles is more
active than a series of O-aroyl-β-aminopropioamidoximes [12].
The data obtained can be used in further in vivo testing of the antidiabetic
properties of the most promising samples with a preliminary assessment of their
average toxic dose in animals.
2. Local anesthetic activity of new amidoxime derivatives
Herein we present results from a study of the local anesthetic activities of three
chemical groups of new amidoxime derivatives (1–10) [4].
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The first group includes derivatives of α-chloro-α-isonitrosoacetone such as 3-
acetyl-5,5-bis(hydroxymethyl)-5,6-dihydro-4H-1,2,4-oxadiazine (1) and the anti-
isomer of N-(4-methylphenyl)acetylformamidoxime thiosemicarbazone (2). The
second group includes the hydrochlorides of O-aroyl-β-aminopropioamidoximes
with piperidine (3), morpholine (4–6), and benzimidazole (7 and 8) in the β-position.
The third group consists of 3-[β-(piperidin-1-yl)]ethyl-5-p-tolyl-1,2,4-oxadiazole (9)
and 3-[β-(piperidin-1-yl)]ethyl-5-m-chlorophenyl-1,2,4-oxadiazole (10).
The local anesthetic activity of 1–10 was studied in three types of anesthesia, i.e.,
infiltration, conduction, and terminal. The reference drugs were trimecaine, lido-
caine, novocaine, and kazcaine [hydrochloride of 1-(2-ethoxyethyl)-4-ethynyl-4-
benzoyloxypiperidine] (Tables 1–3).
Compound Anesthesia index
(М m)
Duration of complete anesthesia
(М m), min
Total duration of anesthesia
(М m), min
1 22.6  1.4* 10.0  2.5** 40.0  2.7*
2 28.0  2.2** 14.4  0.4*** 29.1  2.2**
3 28.8  3.7**** 15.0  0.0* 28.0  4.9***
4 31.4  1.4** 18.3  7.7 55.0  1.8****
5 30.6  1.3* 20.8  2.4**** 55.8  2.1**
6 21.0  2.4* 8.3  2.7 34.1  0.8*
7 31.0  1.2**** 20.0  2.8* 45.8  2.5****
8 34.0  1.15* 25.0  2.8** 55.8  2.1**
9 34.1  0.7** 25.0  0.3* 58.3  2.7*
10 36.0  0.0* 85.0  0.8**** 125.0  1.8**
Trimecaine 34.1  0.5 30.0  1.7 44.1  1.7
Lidocaine 32.3  2.3 25.8  0.8 54.5  2.3
Novocaine 30.0  0.2 10.0  0.0 22.0  0.1
Kazkain 31.1  1.2 25.0  2.5 75.0  0.7
*Compared to trimecaine.
**Compared with lidocaine.
***In comparison with novocaine.
****Compared to cascaine.
Table 1.
Activity and duration of action of compounds 1–10 (0.5% concentration) for infiltration anesthesia.
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The experimental results indicated that all compounds 1–10 were effective to
different degrees in infiltration anesthesia (Table 1). The most active compound
was 10, which induced the maximum deep anesthesia (anesthesia index 36.0) and
exceeded statistically that of the reference drugs with the exception of lidocaine.
Compound Anesthesia index
(М m)
Duration of complete anesthesia
(М m), min
Total duration of anesthesia
(М m), min
1 329.0  20.0* 10.0  0.0*** 64.0  1.5*
2 301.0  5.3** 15.0  0.0* 72.0  4.0*
3 319.7  5.6*** 45.0  0.0** 69.3  3.0**
4 427.0  44.0* 48.0  0.0**** 80.6  2.0***
5 310.0  43.7* 20.0  0.0* 65.0  3.1*
6 242.9  4.7** 10.0  0.8* 61.2  1.2*
7 425.7  15.6* 84.0  2.6** 144.0  3.5****
8 534.0  12.0**** 88.0  0.0*** 118.0  3.1*
9 591.0  34.0* 90.0  2.4* 105.0  5.9*
10 600.0  0.0* 70.4  1.1*** 90.0  3.1**
Trimecaine 324.0  14.0 20.0  0.0 63.0  1.3
Lidocaine 366.8  94.8 10.0  0.0 68.0  2.8
Novocaine 310.0  43.7 10.0  0.0 60.0  0.0
Kazkain 600.0  0.0 208.9  7.3 280.0  0.0
*Compared to trimecaine.
**Compared with lidocaine.
***In comparison with novocaine.
****Compared to cascaine.
Table 2.
Activity and duration of action of compounds 1–10 (1% concentration) for conduction anesthesia.
Compound Regnier index
(М m)
Duration of complete anesthesia
(М m), min
Total duration of anesthesia
(М m), min
1 85.6  5.0 0.0 14.4  1.5
2 242.5  16.4 0.0 33.1  1.6
3 186.3  9.7 0.0 28.0  2.4
4 150.6  16.2 0.0 27.5  1.9
5 281.6  18.5 0.0 38.0  1.9
6 13.0  0.0 0.0 0.0
7 103.0  10.5 0.0 22.0  0.9
8 373.4  37.3 0.0 43.1  4.0
9 601.5  32.7 0.0 62.0  2.3
10 430.0  14.4 0.0 48.75  2.1
Dikain 1300.0  0.0 65.0  0.0 120.0  0.0
Table 3.
Activity and duration of action of compounds 1–10 (1% concentration) for terminal anesthesia.
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This compound also turned out to be more active than the other tested com-
pounds. The anesthesia indices of 8 and 9 were almost the same as that for
trimecaine and were slightly greater than those for lidocaine, novocaine, and
kazcaine. The strength of the anesthesia induced by 4 and 7 was greater than that of
novocaine, equal to that of kazcaine, and less than that of trimecaine and lidocaine.
The anesthesia indices of 1–3 and 4 were less than those of the reference drugs.
Compound 10 had a longer duration of conduction anesthesia than the other tested
compounds (including the reference drugs).
Compounds 5 and 7–9 had longer durations of action than novocaine, shorter
than trimecaine, and essentially the same as lidocaine and kazcaine. The duration of
total anesthesia of 4was longer than that of novocaine and slightly shorter than that
of the other reference drugs. The durations of total anesthesia for 1 and 4 (10.0 and
8.3 min) were comparable with that of novocaine.
Table 2 presents results from a study of conduction anesthesia by 1–10.
Like in the preceding series of tests, 10 had the highest activity. Its anesthesia
index was greater than those of trimecaine, lidocaine, and novocaine and equal to
that of kazcaine. Compounds 1–5 and 7–9 were rather active. Their anesthesia
indices were greater than those of trimecaine, novocaine, and lidocaine. However,
they were less than that of kazcaine. Compound 6 was less active than the reference
drugs. Like in the preceding series of tests, the durations of total anesthesia of the
studied compounds were compared. Table 2 shows that all compounds 1–10 had
total anesthesia duration indices that were shorter than that of kazcaine although 3,
4, and 7–10 had durations of action longer than those of novocaine, lidocaine, and
trimecaine.
Compounds 1–10 in terminal anesthesia were weaker and shorter acting than
dicaine (Table 3). However, not one of these compounds exhibited an irritating
effect.
Thus, it was shown that amidoxime derivatives 1–10 exhibited anesthetic effects
that were greater than those of the reference drugs in conduction and infiltration
anesthesia. The 1,2,4-oxadiazoles 9 and 10 and to a lesser extent O-aroyl-
aminopropioamidoximes with a β-benzimidazole substituent 7 and 8 had longer
durations of action than the reference drugs.
3. Search for new antitubercular drugs among the salts and bases
of O-aroylation products of β-(thiomorfolin-1-yl)- and
β-(4-methylpiperazin-1-yl)propioamidoximes
A search for qualitatively new antitubercular drugs with the requirements of
reducing the duration of treatment, eliminating of the rapid drug resistance devel-
opment and toxic side effects of the existing antitubercular drugs, and reducing
the cost of extremely expensive treatment of TB (DS, MDR, XDR) is being
conducted in the world.
1,5-Diphenylpyrroles have been identified as a class of compounds with high
in vitro antitubercular activity. Replacing of the methylpiperazine substituent for
thiomorpholine and replacing the chlorine atom in position 4 of the N-phenyl
moiety with the fluorine atom, as well as varying the aromatic substituents at the
C-2 atom of the pyrrole ring during the transition from p-CH3 (BM221) to
p-CH3O (BM233) and to p-CH3S (BM579) in 1,5-(4-chlorophenyl)-2-methyl-3-
(4-methylpiperazin-1-yl)methyl-1H-pyrrole (BM212), leads to an increase in
in vitro antitubercular activity onM. tuberculosis H37Rv strains [13, 14].
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Taking into account the above examples, we synthesized compounds of the
β-aminopropioamidoxime series containing in the β-position fragments of
1-methylpiperazine and thiomorpholine (11–21).
In vitro antitubercular screening of a series of O-aroyl-β-aminopropioa-
midoximes (11–21) on DS museum H37Rv and wild* I MTB strains and two wild DR
and MDR strains of MTB II and III on Shkolnikova liquid medium found that
compounds 11–21 in varying degrees have antitubercular activity from >100 to
0.01 μg/ml (Table 4).
Thus, on the DS strains of MTB O-benzoyl-β-(thiomorpholin-1-yl)
propioamidoxime (18) and hydrochloride, iodomethylate of O-p-toluoyl-β-
(1-methylpiperazin-1-yl)propioamidoxime (21) showed the highest activity
at 0.01 μg/ml; compound 19 had an average antitubercular activity with
MBC >20 μg/ml; the remaining compounds 11–17 and 20 had MBC from 100
to >100 μg/ml.
The highest activity in 0.1 μg/ml on DR andMDR strains of MTB II and III was
shown by hydrochloride, iodomethylate ofO-p-toluoyl-β-(1-methylpiperazin-1-yl)
propioamidoxime (21) (Table 4).
The acute toxic effect of rifampicin, isoniazid, and compounds 18 and 21 (LD50)
was determined on white mice of both sexes weighing 17–23 g when administered
subcutaneously. The toxicity of rifampicin SV is 267.6  7.2 mg/kg; of isoniazid
62.5  12.8 mg/kg; and of compounds 18 and 21, respectively, 325.0  17.8 and
1750.0  35.6 mg/kg.
Thus, hydrochloride, iodomethylate of O-p-toluoyl-β-(4-methylpiperazin-1-yl)
propioamidoxime, is by 100 times more active against DS strains than rifampicin
SV and by 10 times more active than isoniazid; it is by 20 times more active against
DR strains than rifampicin SV and by 10 times more active than isoniazid. Hydro-
chloride, iodomethyl O-p-toluoyl-β-(4-methylpiperazin-1-yl)propioamidoxime,
is less toxic than rifampicin SV by 6.5 times and by 28 times less toxic than
isoniazid.
O-Benzoyl-β-(thiomorpholin-1-yl)propioamidoxime is by 100 times more
active against DS strains than rifampicin SV and by 10 times more than isoniazid;
it is less toxic than rifampicin SV by 1.2 times and by 5.2 times less toxic than
isoniazid. These data are protected by the patents of the Republic of Kazakhstan
[7, 8].
6
Heterocycles - Synthesis and Biological Activities
Based on the high priority requirements of increasing the effectiveness and
safety of treatment in the development of new antitubercular drugs, it can be
argued that O-benzoyl-β-(thiomorpholin-1-yl)propioamidoxime and hydrochlo-
ride, iodomethylate of O-p-toluoyl-β-(4-methylpiperazine-1-yl)propioamidoxime,
are competitive because they are less toxic and more active than the basic
tuberculostatics used in practice: isoniazid and rifampicin.
4. Inhibition of α-amylase and α-glucosidase by new
β-aminopropioamidoxime derivatives
The urgency of discovering effective medicines to treat diabetes and information
about the antidiabetic activity of amidoxime derivatives [9–11] prompted us to test
β-aminopropionamidoxime bases and pharmacologically acceptable salts of O-
aroyl-β-(morpholin-1-yl)propionamidoximes and 5-aryl-3-β-(piperidin-1-yl- and
morpholin-1-yl)ethyl-1,2,4-oxadiazoles for in vitro inhibitory activity against the
enzymes α-amylase and α-glucosidase, which determine the supply level of glucose
from the gastrointestinal tract into the blood pool.
Herein, results from in vitro screening of new β-aminopropionamidoximes
(22–26) for antidiabetic activity are now reported. The series of β-aminopropiona-
midoximes included bases and pharmacologically acceptable salts (hydrochloride,
acetate, oxalate, citrate, and methyl iodide) of O-aroyl-β-(morpholin-1-yl)
propionamidoximes 22–24 and 5-(p-, m-substituted phenyl)-3-(β-piperidin-1-yl-
and morpholin-1-yl)-1,2,4-oxadiazoles 25 and 26.
№ соmp. MBC on the M. tuberculosis strains, μg/ml
H37Rv I II III LD50, mg/kg
11 >100 >100 100 100 —
12 100 100 100 100 —
13 100 100 100 100 —
14 >100 >100 100 100 —
15 100 100 100 100 —
16 100 100 100 100 —
17 >100 >100 >100 >100 —
18 0.01 0.01 100 100 325.0  17.8
19 >20 >20 100 100 —
20 100 100 100 100 —
21 0.01 0.01 0.1 0.1 1750.0  35.6
Rifampicin 1 1 2 2 267.6  7.2
Isoniazid 0.1 0.1 1 1 62.5  12.8
*Wild strains of M. tuberculosis I, II, and III were isolated from the patients and typed in the RSE “National Scientific
Center for Phthisiopulmonology of the Republic of Kazakhstan” of the Ministry of Health of the Republic of
Kazakhstan: I, DS (drug-sensitive) to anti-TB drugs; II, DR (drug-resistant) to rifampicin; III, MDR (multidrug-
resistant) to rifampicin, isoniazid, and ethambutol.
Table 4.
Bactericidal activity and average subcutaneous toxicity of O-aroyl-β-(thiomorpholin-1-yl)propioamidoximes
(11–20) and double salt of O-p-toluoyl-(4-methylpiperazin-1-yl)propioamidoxime (21) on DS and DR
strains of M. tuberculosis.
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Compounds 22–24a and b, 25, and 26 were described [12, 15, 16].
Compounds 24b–f were derived from the base of O-p-toluoyl-β-(morpholin-
1-yl)propionamidoxime 24a and were prepared in one step by adding of equivalent
amounts of organic acids (acetic, oxalic, citric) and methyl iodide in various sol-
vents. Acetate 24c was prepared by reacting 24a with a twofold excess of glacial
AcOH in refluxing in EtOH.
The in vitro activity of 22–26 for inhibition of α-amylase and α-glucosidase was
tested using two series of experiments. Table 5 presents the screening results using
acarbose as the standard in both instances.
The greatest inhibitory activities (50%) for α-amylase were found for O-m-
chlorobenzoyl-β-(morpholin-1-yl)propionamidoxime (22b, 48%); 5-(p-
bromophenyl)-3-[(β-piperidin-1-yl)ethyl]-1,2,4-oxadiazole (25b, 51%); and 5-(m-
chlorophenyl)-3-[(β-morpholin-1-yl)ethyl]-1,2,4-oxadiazole (26, 48%). Moderate
activity for α-amylase (from 27 to 43%) was found for O-m-chlorobenzoyl-β-
(morpholin-1-yl)propionamidoxime hydrochloride (23, 35%); base O-p-toluoyl-β-
(morpholin-1-yl)propionamidoxime (24a, 32.5%); citrate of O-p-toluoyl-β-
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(morpholin-1-yl)propionamidoxime (24e, 37%); and 5-(p-toluoyl)-3-[(β-piperidin-
1-yl)ethyl]-1,2,4-oxadiazole (25a, 43%).
The highest inhibitory activities against α-glucosidase were exhibited by O-p-
anisoyl-β-(morpholin-1-yl)propionamidoxime (22a, 78.7%); iodine methylate of
O-p-toluoyl-β-(morpholin-1-yl)propionamidoxime (24f, 78.1%); and 5-(m-
chlorophenyl)-3-[(β-morpholin-1-yl)ethyl]-1,2,4-oxadiazole (26, 61.7%).
Moderate inhibitory activity for α-glucosidase was manifested by O-m-
chlorobenzoyl-β-(morpholin-1-yl)propionamidoxime (22b, 23%) and its hydro-
chloride (23, 45.1%).
The reference compound acarbose exhibited the standard inhibitory activity
against α-amylase and α-glucosidase of 71.0 and 75.5%, respectively.
In conclusion, it is noteworthy that bases and pharmacologically acceptable salts
of O-aroyl-β-aminopropionamidoximes and 5-substituted phenyl-3-β-(piperidin-1-
yl and morpholin-1-yl)ethyl-1,2,4-oxadiazoles (22–26) showed more pronounced
inhibitory activity for α-glucosidase than for α-amylase. Both 22a and 24f had
α-glucosidase activity comparable with that of the standard acarbose.
A structure–activity relationship for two series of screening experiments found
that, as a rule, 3,5-disubstituted 1,2,4-oxadiazoles exhibited greater inhibition of
α-amylase and α-glucosidase than their chemical precursors, i.e., bases and
pharmacologically acceptable salts of O-aroyl-β-aminopropionamidoximes.
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Compound 22a 22b 23 24a 24b 24c 24d Acarbose
Inhibition,
%
α-Amylase — 48.0  5.8 35.0  0.6 32.5  0.22 27.0  5.5 25.6  0.26 — 71.0  2.7
α-Glucosidase 78.7  0.9
1**
23.0  0.84 45.1  1.99 22.8  0.09 34.7  1.36 27.4  0.15 — 75.0  1.32
Compound 24e 24f 25a 25b 25c 26 Acarbose
Inhibition, % α-Amylase 37.0  3.4 — 43.0  3.0 51.0  9.1 — 48.0  5.9 71.0  2.7
α-Glucosidase — 78.1  4.41** 67.2  0.82 68.7  1.81 67.2  1.79 61.7  2.26 75.0  1.32
*Activity absent ().
**p > 0.05 vs. acarbose.
Table 5.
Inhibitory activity of 22–26 for α-amylase and α-glucosidase, %*.
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